News | April 23, 2024
AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
Open a printable version of this pageEmail the URL of this page to a friend
Open a printable version of this pageEmail the URL of this page to a friend
Vision loss due to Glaucoma can be prevented if it is detected and treated early
Take proper precautions and seek timely treatment!
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Ensures efficient testing of FeNO as it is a simple tool for the diagnosis, screening & monitoring of Asthma patients
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Subscribe To Our Newsletter & Stay Updated
